Biogazelle Overview
- Year Founded
-
2007
- Status
-
Acquired/Merged
- Employees
-
43
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
5
Biogazelle General Information
Description
Provider of expert genomic and transcriptomic services intended to support research and clinical trials. The company specializes in liquid biopsies and non-coding RNA and supports scientists in the development of diagnostics and therapeutics, enabling clients to accelerate their biotechnology projects in a short time.
Contact Information
Website
services.biogazelle.comCorporate Office
- Technologiepark 82
- 9052 Zwijnaarde
- Belgium
Corporate Office
- Technologiepark 82
- 9052 Zwijnaarde
- Belgium
Biogazelle Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biogazelle Comparisons
Industry
Financing
Details
Biogazelle Competitors (49)
One of Biogazelle’s 49 competitors is Parexel International, a Private Equity-Backed company based in Raleigh, NC.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Parexel International | Private Equity-Backed | Raleigh, NC | ||||
| Ambry Genetics | Formerly PE-Backed | Aliso Viejo, CA | ||||
| Charles River Laboratories International | Formerly PE-Backed | Wilmington, MA | ||||
| Cellecta | Private Debt Financed | Mountain View, CA | ||||
| Syneos Health | Private Equity-Backed | Morrisville, NC |
Biogazelle Patents
Biogazelle Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3002744-A1 | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna | Pending | 19-Oct-2015 | ||
| EP-3365446-A1 | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna | Inactive | 19-Oct-2015 | ||
| EP-3365446-A4 | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna | Inactive | 19-Oct-2015 | ||
| US-11021707-B2 | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna | Active | 19-Oct-2015 | ||
| US-20190048341-A1 | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna | Active | 19-Oct-2015 | C12N15/113 |
Biogazelle Signals
Biogazelle Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Biogazelle FAQs
-
When was Biogazelle founded?
Biogazelle was founded in 2007.
-
Where is Biogazelle headquartered?
Biogazelle is headquartered in Zwijnaarde, Belgium.
-
What is the size of Biogazelle?
Biogazelle has 43 total employees.
-
What industry is Biogazelle in?
Biogazelle’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Biogazelle a private or public company?
Biogazelle is a Private company.
-
What is Biogazelle’s current revenue?
The current revenue for Biogazelle is .
-
How much funding has Biogazelle raised over time?
Biogazelle has raised $2.77M.
-
Who are Biogazelle’s investors?
Fournier-Majoie Foundation, Horizon 2020, PMV (Belgium), Qbic Fund, and VLAIO have invested in Biogazelle.
-
Who are Biogazelle’s competitors?
Parexel International, Ambry Genetics, Charles River Laboratories International, Cellecta, and Syneos Health are some of the 49 competitors of Biogazelle.
-
When was Biogazelle acquired?
Biogazelle was acquired on 14-Dec-2021.
-
Who acquired Biogazelle?
Biogazelle was acquired by CellCarta.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process